Mitigating the risk: The role of ovarian transposition and medical suppression

Oncofertility Medical Practice: Clinical Issues and Implementation

Volumn , Issue , 2012, Pages 91-104

  Knopman, Jaime M ^a   Noyes, Nicole ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890419450     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-9425-7_7     Document Type: Chapter

References (54)

1. McCall M, Keaty E, Thompson J. Conservation of ovarian tissue in the treatment of the carcinoma of the cervix with radical surgery. Am J Obstet Gynecol. 1958;75:590-600.
2. Nahhas W, et al. Lateral ovarian transposition: ovarian relocation in patients with Hodgkin’s disease. Obstet Gynecol. 1971;38:785-8.
3. Baker J, et al. Preservation of ovarian function in patients requiring radiotherapy for paraaortic and pelvic Hodgkin’s disease. Lancet. 1972;1:1307-8.
4. Stillman R, Schinfeld J, Schiff I. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol. 1981;139:62-6.
5. Wo J, Viswanathan A. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;5:1304-12.
6. Donnez J, Bassil S. Indications for cryopreservation of ovarian tissue. Hum Reprod Update. 1998;4:248-59.
7. Lushbaugh C, Casarett G. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer. 1976;37 Suppl 2:1111-25.
8. Sella T, Mironov S, Hricak H. Imaging of transposed ovaries in patients with cervical cancer. Am J Roentgenol. 2005;184:1602-10.
9. Clough K, et al. Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Cancer. 1996;77:2638-45.
10. Barwijuk A, Jankowska S, Paplicki A. Laparoscopic anterolateral ovarian transposition before irradiation of chordoma. Acta Obstet Gynecol Scand. 2005;84:822-3.
11. Gareer W, et al. Preservation of ovarian germinal follicles by temporary laparoscopic ovarian transposition in teen-aged girls undergoing craniospinal irradiation for radiosensitive CNS tumors. Taiwan J Obstet Gynecol. 2008;47:300-4.
12. Al-Badawi I, et al. Laparoscopic ovarian transposition before pelvic irradiation. Int J Gynecol Cancer. 2010;20:1082-6.
13. Gareer W, Gad Z, Gareer H. Needle oophoropexy: a new simple technique for ovarian transposition prior to pelvic irradiation. Surg Endosc. 2007;25:2241-6.
14. Anderson B, et al. Ovarian transposition in cervical cancer. Gynecol Oncol. 1993;49:206-14.
15. Feeney D, et al. The fate of the ovaries after radical hysterectomy and ovarian transposition. Gynecol Oncol. 1995;56:3-7.
16. Gershenson D. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr. 2005;34:43-7.
17. SEER Cervical Cancer Statistics Review. http://seer.cancer.gov/csr/1975_2008/browse_csr. php?section=5page=sect_05_zfig.03.html. Accessed 24 Jun 2011.
18. Han S-S, et al. Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuVant pelvic irradiation. J Obstet Gynaecol Res. 2011;37:825-9.
19. Organization for Economic Cooperation and Development. Chart SF2.3A: Mean age of women at the birth of first child. 2008. http://www.oecd.org/dataoecd/62/49/41919586.pdf. Accessed 21 Jun 2011.
20. O’Connell J, et al. Do young colon cancer patients have worse outcome? SEER data. World J Surg. 2004;28:558-62.
21. Critchley H, et al. Abdominal irradiation in childhood; the potential for pregnancy. Br J Obstet Gynaecol. 1992;99:392-4.
22. Kurt M, et al. Successful spontaneous pregnancy in a patient with rectal carcinoma treated with pelvic radiotherapy and concurrent chemotherapy; the unique role of laparoscopic lateral ovary transposition. Eur J Gynaecol Oncol. 2007;28:408-10.
23. Ray G, et al. Oophoropexy: a means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin’s disease. Radiology. 1970;96:175-80.
24. Haie-Meder C, et al. Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys. 1993;25:419-24.
25. Cutillo G, et al. Conservative treatment of reproductive and sexual function in young woman with squamous carcinoma of the vagina. Gynecol Oncol. 2006;103:234-7.
26. Gareer W, Gad Z, Gareer H. Needle oophoropexy: a new simple technique for ovarian transposition prior to pelvic irradiation. Surg Endosc. 2011;25:2241-6.
27. Morice P, et al. Fertility results after ovarian transposition for pelvic malignancies treated by pelvic malignancies treated y external irradiation or brachytherapy. Hum Reprod. 1998;13:660-3.
28. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update. 2008;14:543-52.
29. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981;1:1132-4.
30. Kitajima Y, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 2006;147:694-9.
31. Sutcliffe SB. Cytotoxic chemotherapy and gonadal function in patients with Hodgkin’s disease: facts and thoughts. JAMA. 1979;242:1898-9.
32. Ortin TT, Shoshlak CA, Donaldson SS. Gonadal status and reproductive function following treatment of Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys. 1990;19:873-80.
33. Wallace WH, et al. Ovarian function following the treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1993;21:333-9.
34. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med. 2005;353: 64-73.
35. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes or ovaries. Oncologist. 2007;12:1044-54.
36. Saitta A, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol. 2001;21:1512-9.
37. Grudker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003;1:65-71.
38. Imai A, et al. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest. 2007;63:102-6.
39. Perez GI, et al. Apoptosis associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med. 1997;3:1228-32.
40. Morita Y, et al. Targeted expression of Bcl-2 in mouse oocytes inhibits ovarian follicle atresia and prevents spontaneous and chemotherapy-induced oocyte apoptosis in vitro. Mol Endocrinol. 1999;13:841-50.
41. Morita Y, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000;6:1109-14.
42. Waxman JH, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol. 1987;19:159-62.
43. Badawy A, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694-7.
44. Ben-Aharon I, et al. Pharmacological intervention for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122:803-11.
45. Bedaiwy M, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systemic review and meta-analysis. Fertil Steril. 2011;95:906-14.
46. Gerber B, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuVant breast cancer chemotherapy. The GBG 37 ZORO study. J Clin Oncol. 2010;29:2334-41.
47. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update. 2005;11:69-89.
48. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. Blood. 1981;58:849-51.
49. Longhi A, et al. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuVant chemotherapy treatment for osteosarcoma. Oncol Rep. 2003;10:151-5.
50. Recchia F, et al. Gonadotropin-releasing hormone analogues added to adjuVant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106:514-23.
51. Del Mastro L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006;17:74-8.
52. Urruticoechea A, et al. Ovarian protection with goserelin during adjuVant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat. 2008;110: 411-6.
53. Giuseppe L, et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 2007;12:141-7.
54. Pereyra Pacheco B, et al. Use of GnRH analogues for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001;81:391-7.